Key result
Ramipril lowers blood pressure in diabetic hypertensives without adverse effects on glucose control.
Why the study?
This analysis assessed the efficacy, tolerance, and safety of the ACE inhibitor ramipril in diabetic patients with mild-to-moderate essential hypertension.
Does ramipril safely and effectively reduce blood pressure without adversely affecting blood glucose in diabetic patients with mild-to-moderate essential hypertension?
RCT (n=105)
Double-blind
Randomly assigned
Does ramipril safely and effectively reduce blood pressure without adversely affecting blood glucose in diabetic patients with mild-to-moderate essential hypertension?
Ramipril effectively lowers blood pressure in diabetic patients with mild-to-moderate hypertension without adversely affecting blood glucose levels.
Answers are grounded in this paper and cite their sources.
Supports ramipril for BP control in diabetic hypertensives; confirms glucose-neutral efficacy in this RCT population.
Six double-blind studies were designed to assess the efficacy, tolerance, and safety of the angiotensin-converting enzyme inhibitor ramipril in patients with mild-to-moderate essential hypertension. Of 1,189 hypertensive patients in these studies, 105 patients were diabetic. They were randomly assigned either to a ramipril monotherapy group (1.25-10 mg/day) or to one of the following treatment groups: ramipril (5 mg/day) plus piretanide (3 mg/day), captopril (100 mg/day), enalapril (10-20 mg/day), hydrochlorothiazide (50 mg/day), or atenolol (100 mg/day). In all studies, a 4-week single-blind placebo run-in phase was followed by a 6-week double-blind active treatment phase. Significant reductions in blood pressure were achieved with all antihypertensive agents. No statistically significant deleterious effects were observed on concentrations of blood glucose, although diabetics who received hydrochlorothiazide showed slight increases in blood glucose levels. Ramipril was well tolerated by diabetic patients, and no serious adverse events occurred. Adverse events reported were typical of ACE inhibitors.
No takes yet. Share an insight, caveat, or question.
Erhard et al. (1991) conducted an RCT in Mild-to-moderate essential hypertension with diabetes (n=105). Ramipril vs. Captopril (100 mg/day), enalapril (10-20 mg/day), hydrochlorothiazide (50 mg/day), or atenolol (100 mg/day) was evaluated on Blood pressure reduction. Ramipril reduced blood pressure over 6 weeks in 105 diabetic hypertensives without deleterious effects on blood glucose or serious adverse events.
Synapse has enriched 10 related papers. Consider them for comparative context: